The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

Cover Page
  • Authors: Poddubnaya I.V.1, Bialik T.E.2, Glonina N.N.3, Kalashnikova O.B.4, Kaplanov K.D.5, Lapin V.A.6, Medvedeva N.V.7, Mikhailova N.B.8, Moiseeva T.N.9, Nikitin E.A.10, Pospelova T.I.11, Stadnik E.A.12
  • Affiliations:
    1. Russian Medical Academy of Continuous Professional Education
    2. The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation
    3. KGBUZ Regional Clinical Hospital No. 1 named after prof. S.I. Sergeeva
    4. Clinic “Research Institute of Pediatric Oncology, Hematology and Transplantology named after R.M. Gorbacheva ”FSBEI HE“ First St. Petersburg State Medical University named after Acad. I.P. Pavlova »Ministry of Health of Russia
    5. Volgograd Regional Clinical Oncology Center
    6. Department of Health and Pharmacy Yaroslavl Region
    7. State Clinical Hospital City Clinical Hospital No. 31
    8. Clinic Research Institute of Pediatric Oncology, Hematology and Transplantology named after R.M. Gorbacheva FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of Russia
    9. Federal State Budgetary Institution National Medical Research Center for Hematology, Ministry of Health of Russia
    10. GBUZ «City Clinical Hospital named after S.P. Botkin» Department of Health in Moscow
    11. FSBEI HE Novosibirsk State Medical University of the Ministry of Health of Russia
    12. FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of Russia
  • Issue: Vol 21, No 4 (2019)
  • Pages: 45-47
  • Section: CLINICAL ONCOLOGY
  • URL: https://journals.rcsi.science/1815-1434/article/view/34009
  • DOI: https://doi.org/10.26442/18151434.2019.4.190725
  • ID: 34009

Cite item

Full Text

Abstract

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy schemes today remain the standard treatment approach for CLL. The advent of novel molecules expands possibilities of treating this disease. Targeted therapy with small molecule inhibitors of Bruton tyrosine kinase (BTK) occupies an important place in the treatment of patients with CLL, both for first-line therapy and for treatment of relapses. The drug acalabrutinib as a highly selective new generation of BTK inhibitor can be considered as an efficient and safe option for first-line therapy and for treatment of the disease relapse in patients with CLL, especially in patients with comorbidity, including cardiovascular diseases (CDV) or risk factors for CVD.

About the authors

Irina V. Poddubnaya

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: or@hpmp.ru

Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor

Russian Federation, Moscow

Tatyana E. Bialik

The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation

Email: or@hpmp.ru

candidate of medical sciences

Russian Federation, Moscow

Natalya N. Glonina

KGBUZ Regional Clinical Hospital No. 1 named after prof. S.I. Sergeeva

Email: or@hpmp.ru
Russian Federation, Khabarovsk

Olga B. Kalashnikova

Clinic “Research Institute of Pediatric Oncology, Hematology and Transplantology named after R.M. Gorbacheva ”FSBEI HE“ First St. Petersburg State Medical University named after Acad. I.P. Pavlova »Ministry of Health of Russia

Email: or@hpmp.ru
Russian Federation, St. Petersburg

Kamil D. Kaplanov

Volgograd Regional Clinical Oncology Center

Email: or@hpmp.ru

Candidate of Medical Sciences

Russian Federation, Volgograd

Valery A. Lapin

Department of Health and Pharmacy Yaroslavl Region

Email: or@hpmp.ru

Chief Freelance Specialist

Russian Federation, Yaroslavl

Nadezhda V. Medvedeva

State Clinical Hospital City Clinical Hospital No. 31

Email: or@hpmp.ru

Candidate of Medical Sciences

Russian Federation, St. Petersburg

Natalya B. Mikhailova

Clinic Research Institute of Pediatric Oncology, Hematology and Transplantology named after R.M. Gorbacheva FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of Russia

Email: or@hpmp.ru

Candidate of Medical Sciences

Russian Federation, St. Petersburg

Tatyana N. Moiseeva

Federal State Budgetary Institution National Medical Research Center for Hematology, Ministry of Health of Russia

Email: or@hpmp.ru

candidate of medical sciences

Russian Federation, Moscow

Evgeniy A. Nikitin

GBUZ «City Clinical Hospital named after S.P. Botkin» Department of Health in Moscow

Email: or@hpmp.ru

Doctor of Medical Sciences, Professor

Russian Federation, Moscow

Tatyana I. Pospelova

FSBEI HE Novosibirsk State Medical University of the Ministry of Health of Russia

Email: or@hpmp.ru

Doctor of Medical Sciences, Professor

Russian Federation, Novosibirsk

Elena A. Stadnik

FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of Russia

Email: or@hpmp.ru

Candidate of Medical Sciences

Russian Federation, St. Petersburg

References

  1. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018 г. [Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018 g. (in Russian).]
  2. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. П.А.Герцена – филиал ФГБУ НМИРЦ Минздрава России, 2017. [Malignant neoplasms in Russia in 2015 (morbidity and mortality). Ed. A.D.Kaprina, V.V.Starinskii, G.V.Petrovoi. Moscow: MNIOI im. P.A.Gertsena – filial FGBU NMIRTs Minzdrava Rossii, 2017 (in Russian).]
  3. Wanchoo R et al. Renal involvement in chronic lymphocytic leukemia. Clin Kidney J 2018; 11 (5): 670–80.
  4. Thurmes P et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008; 49 (1): 49–56.
  5. Burger JA, O’Brien S. Evolution of CLL treatment – from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol 2018; 15 (8): 510–27.
  6. Boddy C, Ma S. Frontline Therapy of CLL: Evolving Treatment Paradigm. Curr Hematol Malig Rep 2018; 13 (2): 69–77.
  7. Wendtner C-M. Ibrutinib: the home run for cure in CLL? Blood 2019; 133 (19): 2003–4.
  8. Patel V et al. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res 2017; 23 (14): 3734–43.
  9. Byrd JC et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374 (4): 323–32.
  10. Wu et al. Acalabrutinib (ACP-196): a selective secondgeneration BTK inhibitor. J Hematol Oncol 2016; 9: 21.
  11. Mato AR et al. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biol Ther 2018; 19 (1): 1–2.
  12. Covey T et al. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res 2015; 75 (15 Suppl.): 2596.
  13. Awan FT et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 2019; 3 (9): 1553–62.
  14. Paolo Ghia et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (Idr) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). EHA 2019. Abstract LB2606.
  15. Weide R et al. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Blood 2018; 132 (Suppl. 1): 4823.
  16. Rummel MJ et al. Study group indolent L: bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381 (9873): 1203–10.
  17. Fischer K et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127 (2): 208–15.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies